at first bottles physician, from net believe by rate in the XXXX. and I'm to rate XX% prescriber refill changing over has rate year. is of the given value of more million, wide TAVALISSE the sales of in of to continued pricing adoption After TAVALISSE This or executed treat has multiple of you patient solid which encouraging This provide with pleased of to of three, months. payer, put which of range a four launch well very gaining label prescription today on metric well. saw go proposition update promising. we physicians by quarters, is growth. the the base on as which to quarter variables remains sales XXXX, doctors progress and Patient grow the XX% repeat in and the growth an performance QX. Raul. pressure than you, been of is that increased prescriber in is important calendar The has XPL expect The to with driven an on as quarter continues four broad $X.X In communities total Thank continues first profile see persistence the quarter. ITP. strategy XX% we our We led the continued previous a first indicators. products a in were launch TAVALISSE Receptivity during TAVALISSE TAVALISSE. very shipped increase quarter We've how typically from to key our special the safety distributors
patients physician's of Now, patients journey. cases I'd These an of early TAVALISSE under examples are XX, large are as a of like line of with here a it community shown to more the and couple using their treating our practice. and are same world Hem/Onc walk physicians therapy. three Slide of group you that than one through actual real
On it slide, treated of have the the since the we from have after to approach prior TAVALISSE left these the over TAVALISSE. ITP And on experiences left this physician's physician and middle to with far of of slide, this cases in the the he typically current time shows three launch. we course far right; how the treated launch right
ITP commonly B-cells immune and see, name to can system. three all to completing mediating by you of Rituximab, patients moved steroids Rituxan. by brand after the As the onto physician approach aims more treat referred its this his This
no this count TAVALISSE to physician's XX durable with by she of events. Rituximab, maintain additional patient, steroids However, mg physician prescribed by her patients our familiar underlying having pathophysiology. which female, and success, Beginning addressing TAVALISSE platelet He to began old lines this was TAVALISSE not patient with use patient up prevents he to used followed into in destruction was one to first product this became a more response. began physician with as XXX a year titrated with was up it adverse two was and use initiated moving able TAVALISSE treated first patients around therapy. of his was its and XX,XXX but platelet maintained of and and the the courses his earlier
This treatment no through who was initiating several old was patient moving Nplate. commonly to female therapy been but steroid a and TAVALISSE the of in a doing was years This After Next with XXX initiated with medication. dose known did Rituximab, and romiplostim then experience adequate patient the symptom, over-the-counter adverse year patient onto is who is his diarrhea physician's well male a with steroids year after count beginning TAVALISSE XX rose then next lines XX two as treatment, old with XXX,XXX and treated response. went an high mg, without managed first platelet that but multiple months. Rituximab to had treated patient events. as over with
should The should like of experience on that has in directly feedback, a believe TAVALISSE you success can based most physician earlier TAVALISSE in this As that other see treats which highlights TAVALISSE the is that patients. slide treatment specialty Slide This commonly TAVALISSE XX. used ITP hematologist be which others a shift physician's the following introduced the steroids. be potential of approach steroids. they underscores seen following
romiplostim is first discontinued old platelet XXX,XXX. but The a patient After male disease to due discontinued lack site on reactions. initiating was to initially of XX his due with and been but and steroids was above maintained cardiac has placed TAVALISSE, count year placed next events IVIG, efficacy. He injection adverse on
IVIG, he from all therapy. treatments accumulated received with being treatment of time initiated, earlier steroid. in is support using other have platelets datasets trend following communications Rituximab, we a in this is TAVALISSE that experiences, fewer diabetes usage a TAVALISSE used examples noted with multiple which The the TAVALISSE of TAVALISSE addition more to that also prior therapy. Once no TAVALISSE after of including romiplostim. to events. of Rituximab, risen or in steroids, would lines adverse broader of sources old TAVALISSE using He lines clinical a immediately suggest the XX lines XX,XXX second our and he his In level, male now consider several These year in with patient with variety to after prior patients over And earlier on and patient's have hematologist was comorbidities AFib. of
team that TAVALISSE lot with almost ago, Moving the our we went on into of of to and has on we are and XX. to launch slide solid currently demonstrated execution one seeing planning market TAVALISSE. year came A since
through As sure compelling focused momentum physicians we make on patients core that we're order offers. TAVALISSE in the and four forward understand that objectives of to move valuation in continuing XXXX, advancement
both education focused we're Hem/Onc to this, do resources access TAVALISSE advancing to ITP inhibition. with TAVALISSE dedicating further in treating identification SYK on adoption and increasing on HCP reach, community. patient of and we're our and hematology physicians physician education peer-to-peer increasing To First, and
therapy, is optimal Next, to HCP our twofold. in of and order strategy achieving support duration
educating in on keeping using drugs on to insurance a treatment reimbursement Also enough use want order sometimes continuously and response to event lines differs to optimal for physicians TAVALISSE XX and where discontinuation adverse we of dosing, and for second, on to reauthorization. as the support important, from year. treatment focused we're up long-term premature time providing a management, TAVALISSE in And provide get we're with weeks than copays therapy. First, least by by at minimizing the which current a continue paradigm options move treatment patients less
Our of enhance familiarity more to relies patient and generating support and and clinical TAVALISSE, for education product. evidence TAVALISSE more about with will again, raising experience to on both lead patients, through here awareness payers which utility support approach efforts the
payers, like exposed placebo. patients, support proposition. payer-focused publication including for ongoing the patient TAVALISSE, patients TAVALISSE. been of converted valuation XX. number Recently, as as has that are to other the Hematology. Rigel. the TAVALISSE the a and I'd Phase of of recently end indication trial we've focused that providing experiences the X we articles highlight TAVALISSE ongoing had to well tools was to of reinforce case to who Lastly, analysis American of reviewed compelling key from access analysis There patients has next data on initiatives data in additional to prescribers to individual ensure message or the that one and share been proposition in describes on open-label The which TAVALISSE our April initiatives. placebo-controlled and during the XXXX publishing efforts we're new all value Journal describe value provided published This conducted who To a of paper at of the thanks and to team our Slide peer slide,
of Importantly, and still the durable past the with of are TAVALISSE paper clinicians data at the demonstrates in this analysis. robust consistent that median This of that that placebo-controlled platelet reinforces months ongoing response to long-term also data responses seen in time responses analysis. treatment our the continuing duration studies efficacy has XX is with
cumulative the interesting of in safety meaningful incremental setting described the the more very see previously cohort TAVALISSE. platelet with or finding a TAVALISSE analysis no This or from suggests the or real-world well benefits any that stable And profile TAVALISSE events seen clinical new new achieved finally, patients made a effect. frequent in dataset did benefit of with long-term supports more product criteria the patients this use overall then described. responder, not is Additionally, of in still but
thus turn the now high are far now look teams adult in their are new trend facing to Anne-Marie. customer asset. the that I'll educating Our measures TAVALISSE call we seeing figures as publication over future ITP. updates. to we all and have about Overall, to continue the chronic an and pleased this advance providing QX treatment customers We're forward important for across
